.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
UBS
Moodys
Accenture
Dow
Mallinckrodt
McKinsey
Fish and Richardson
QuintilesIMS
Boehringer Ingelheim

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019071

« Back to Dashboard
NDA 019071 describes UROCIT-K, which is a drug marketed by Mission Pharma and is included in one NDA. It is available from five suppliers. Additional details are available on the UROCIT-K profile page.

The generic ingredient in UROCIT-K is potassium citrate. There are two hundred and twenty-eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the potassium citrate profile page.

Summary for NDA: 019071

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 019071

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
UROCIT-K
potassium citrate
TABLET, EXTENDED RELEASE;ORAL 019071 NDA Mission Pharmacal Company 0178-0600 0178-0600-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0178-0600-01)
UROCIT-K
potassium citrate
TABLET, EXTENDED RELEASE;ORAL 019071 NDA Mission Pharmacal Company 0178-0610 0178-0610-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0178-0610-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength5MEQ
Approval Date:Aug 30, 1985TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Aug 31, 1992TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength15MEQ
Approval Date:Dec 30, 2009TE:ABRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Cerilliant
McKesson
Julphar
Teva
Federal Trade Commission
Baxter
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot